Search Results

You are looking at 71 - 80 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Optimizing Surveillance and Balancing Evidence With Patient Expectations

Crystal Denlinger and Terry S. Langbaum

and chest CT (with or without contrast) every 6 to 12 months for 2 years, then examination and a chest CT without contrast annually. PET or brain MRI is not indicated. Prostate Cancer In prostate cancer, the intensity of checking prostate-specific

Full access

NCCN News

continues to cause distress and confusion for many men, especially when they read about the controversies associated with the use of prostate-specific antigen (PSA) for the early detection of prostate cancer, noted Dr. Mohler. “The NCCN Guidelines Panel

Full access

Ten Years of Progress in Prostate Cancer

James L. Mohler

In the 1980s, 2 milestones for treating prostate cancer occurred. The first was the development, by T. Ming Chu and his colleagues at Roswell Park Cancer Institute, of prostate-specific antigen (PSA) testing for monitoring treatment (FDA

Full access

Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer

Cynthia L. Gong and Joel W. Hay

the abiraterone group, leading to an overestimation of the ICERs calculated for sipuleucel-T. However, the inclusion and exclusion criteria were very similar for each drug with regard to ECOG status, and pain, prostate-specific antigen levels, and bone

Full access

Toward Personalized Guidelines in Bladder Cancer

Peter E. Clark

prognostic value when performing risk stratification for patients. In genitourinary cancers, the best examples would be serum prostate-specific antigen in prostate cancer and the testis tumor markers α-fetoprotein and β–HCG. In many respects, though, the

Full access

Androgen Deprivation Therapy: Minimizing Exposure and Mitigating Side Effects

Miren Gaztañaga and Juanita Crook

lower dose of IMRT (50.4 Gy) combined with high-dose-rate brachytherapy (21 Gy/3 fractions; n = 160). The 5-year actuarial prostate-specific antigen (PSA) relapse-free survival was improved for patients treated with the high-dose-rate boost versus IMRT

Full access

Prostate Cancer, Version 1.2016

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Anthony Victor D'Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael Hurwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Joshua J. Meeks, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

especially encouraged. Overview Prostate cancer has surpassed lung cancer as the most common cancer in men. The increase in prostate cancer incidence has resulted primarily from prostate-specific antigen (PSA) screening that detects many early

Full access

Abiraterone in Metastatic Salivary Duct Carcinoma

Damien Urban, Danny Rischin, Christopher Angel, Ieta D’Costa, and Benjamin Solomon

progression-free survival in chemotherapy-naïve patients. 6 The 10-month progression-free survival seen in the present patient while on abiraterone is remarkably similar to the median time to prostate-specific antigen progression of 10.5 months in castration

Full access

The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith

combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer . Int J Urol 2008 ; 15 : 419 – 422 . 71 de Jong IJ Koopmans N Breeuwsma AJ . Bone turnover markers for the

Full access

Modification and Implementation of NCCN Guidelines™ on Prostate Cancer in the Middle East and North Africa Region

Waleed A. Hassen, Farrok A. Karsan, Farhat Abbas, Yasar Beduk, Ahmed El-Khodary, Marwan Ghosn, Jamal Khader, Raja Khauli, Danny M. Rabah, Ali Shamseddine, and Sandy Srinivas

100,000. 2 The accuracy of these data is not clear, however, because they are derived from unweighted averages from other regions. In general, prostate-specific antigen (PSA) screening is not routine, and therefore whether the lower incidence rate is